Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px

Document › Details

Lysogene S.A.. (2/7/17). "Press Release: Lysogene Announces Its Successful IPO on Euronext Paris with nearly €22.6m Raised [Not for US, CA, AU, JP]". Paris.

	Region	Paris
	Country	France
	Organisation	Lysogene S.A. (Euronext Paris: LYS)
	Organisation 2	Euronext Paris S.A.
	Group	Euronext (Group)
	Product	gene therapy
	Product 2	financial services
	Index term	Lysogene–SEVERAL: investment, 201701–201702 IPO €22.6m w 3.32m new shares at €6.8/share at Euronext Paris
	Person	Aiach, Karen (Lysogene 201206 CEO + Founder)

Original document
accessed by [iito] on 2017-02-12

Record changed: 2023-06-05

Picture EBD Group BIO-Europe 2023 Munich BEU23 650x200px

More documents for Lysogene S.A. (Euronext Paris: LYS)

[1] European Invesmtent Bank (EIB). (12/24/21). "Press Release: France – Lysogene Enters into a Loan Agreement of €15 Million with the EIB"....
[2] Lysogene S.A.. (7/1/20). "Press Release: Lysogene Announces a Research Collaboration with the Weizmann Institute of Science". Paris....
[3] Lysogene S.A.. (3/12/20). "Press Release: Lysogene Completes €7.7 Million Capital Increase in a Placement Led by Leading Healthcare Investor OrbiMed and Lysogene Shareholder and Partner Sarepta [Not for US, CA, AU or JP]". Paris....
[4] Lysogene S.A.. (10/17/19). "Press Release: Lysogene Appoints Mr. Stéphane Durant des Aulnois as Chief Financial Officer". Paris....
[5] Lysogene S.A.. (4/21/17). "Press Release: 2016 Annual Results". Paris & Cambridge, MA....
[6] Lysogene S.A.. (4/20/17). "Press Release: Lysogene Announces Selection of MRI Interventions’ SmartFlow Cannula for Phase II/III Clinical Study in MPS IIIA". Paris & Cambridge, MA....
[7] Lysogene S.A.. (2/21/17). "Press Release: Lysogene Receives Orphan Drug Designation from EMA for LYS-GM101 for Treatment of GM1 Gangliosidosis". Paris & Cambridge, MA....
[8] Euronext N.V.. (2/8/17). "Press Release: Lysogene Lists on Euronext. €22.6 Million Raised, Market Capitalisation of approximately €82 Million". Paris....
[9] Lysogene S.A.. (2/2/17). "Press Release: Lysogene Receives Orphan Drug Designation from FDA for LYS-GM101 for Treatment of GM1 Gangliosidosis". Paris....
[10] Lysogene S.A.. (1/25/17). "Press Release: Lysogene Launches Its IPO on Euronext’s Regulated Market in Paris"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]